Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Episurf Medical enters into letter of intent regarding acquisition of property in Greater Stockholm of approximately SEK 95 million

EPIS BRegulatory press release07.09.2026 klo 16.47
Read the release

Episurf Medical AB (publ) ("Episurf" or the "Company") has today entered into a letter of intent regarding the acquisition of all shares in LC Åkersberga Fastighets AB, a wholly-owned subsidiary of Landsort Care 4 AB and owner of the property Åkersberga Berga 11:47. The agreed underlying property value amounts to approximately SEK 95 million before deduction of deferred tax. The acquisition supports the Company's strategy to build a Nordic property platform focused on cash flow generating assets and long-term value creation. 

The property is fully let and centrally located in Åkersberga, comprising a mix of retail, public services and a parking garage. The lettable area amounts to 3,553 sqm, excluding the garage, with annual rental income of approximately SEK 9.3 million and a normalised net operating income for 2026 of approximately SEK 7.6 million. 

The financing of the transaction is intended to consist of the assumption of existing external debt financing, newly issued class B shares in Episurf at a preliminary subscription price of SEK 0.10 per class B share, and a cash consideration in connection with completion. The final financing structure will be determined in connection with the entering into of a final share purchase agreement. 

The parties' objective is to enter into a final share purchase agreement no later than 30 September 2026, with completion planned for around 1 December 2026. The entering into of a final share purchase agreement is conditional upon, among other things, customary due diligence, financing and board approval. Further information will be published in connection with the entering into of a final share purchase agreement. 

Key metrics for the Property 

The property has an agreed underlying property value of approximately SEK 95 million, a lettable area of 3,553 sqm excluding the garage, and an occupancy rate of 100 per cent. The normalised net operating income for 2026 amounts to approximately SEK 7.6 million, annual rental income to approximately SEK 9.3 million, and the weighted average unexpired lease term (WAULT) to 3.2 years. 

CEO comment 

"The property in Åkersberga complements our portfolio with fully let premises for retail and public services in a central location. We look forward to completing the transaction and welcoming Industricentralen and SEB Stiftelsen as shareholders in Episurf Medical." 

- Jens Andersson, CEO, Episurf Medical 

For more information, please contact: 

Jens Andersson, CEO, Episurf Medical 

Tel: +46 (0) 768 55 67 02 

Email: jens.andersson@episurf.com 

About Episurf Medical AB 

Episurf Medical is a property company with exposure to a diversified portfolio of property assets. The Company aims to create value growth through the acquisition and management of Nordic properties. The Company also has a medical technology business based on the personalised Episealer® implant and associated surgical instruments, which are used to treat cartilage lesions in joints. Episurf Medical's head office is located in Stockholm, Sweden. 

This information is such information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at 15:45 on 7 September 2026. 

THIS PRESS RELEASE HAS BEEN PUBLISHED IN SWEDISH AND ENGLISH. IN THE EVENT OF ANY DISCREPANCY BETWEEN THE LANGUAGE VERSIONS, THE SWEDISH VERSION SHALL PREVAIL.